The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates.  A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading ->
DURBAN, South Africa — A top executive at Africa’s biggest drug company shared a few home truths with the continent’s health policymakers about the obstacles to local manufacturing at the Conference on Public Health in Africa (CPHIA) 2025. Aspen Pharmacare’s Dr Stavros Nicolaou blamed regulatory bottlenecks and procurement policies for the failure of drug manufacturers […] Continue reading ->
Vaccinations have saved the lives of an estimated 17 million people between 2021 and 2024 – but global immunisation programmes face several challenges, according to an assessment by the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunisation. Dr Kate O’Brien, WHO director of Immunisation, Vaccines and Biologicals, acknowledged the “deep commitment […] Continue reading ->
Engaging people from a nomadic community in rural Kenya in a clinical trial involved employing community mobilisers on motorbikes and understanding seasonal and cultural practices. Geographic touchpoints such as waterholes and schools were mapped as places to find trial participants as they searched for grazing and water for their cattle and goats. This was a […] Continue reading ->